← Issue №1/ week of Jun 24, 2026/ the whole section, in full

Hepatology, in full.

All 2 Hepatology papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 2, in full

most clinically useful first
Hepatology rct · n=3,000 · Jun 30, 2026 · J Hepatology · IF 40.1

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

New evidenceviral hepatitishealth servicesepidemiology
Clinical takeawayPrognostic scores may help identify patients unlikely to benefit from standard adherence support. For elevated-risk patients, alternative strategies are needed as current adherence support did not improve outcomes.
What it foundIn minimal-risk hepatitis C patients, high-intensity adherence support (patient navigation + flexible directly observed therapy) showed a small SVR increase to 68.3% vs. 62.6% with low-intensity support (aRR 1.09, 95% CI: 1.00-1.19; p=0.04), but no benefit was seen in elevated-risk patients (SVR 50.8% vs. 48.4%).
ContextThis trial demonstrates that adherence support effectiveness varies by patient risk profile, but the clinical significance of the minimal-risk group difference is uncertain.
Refinessuggested applicable standard· American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA), "Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection" (Patients With Decompensated Cirrhosis section), 2023

Decision at stakethe choice of adherence support for HCV treatment in people who inject drugs

Diagnose active infection with HCV antibody testing with reflex HCV RNA PCR (Rating I, A); one-time opt-out anti-HCV testing is recommended for all adults ≥18 years and with each pregnancy (I, B), with annual testing for people who inject drugs, men with HIV who have unprotected sex with men, and MSM on PrEP (IIa, C). Treatment is recommended for all persons with acute or chronic HCV infection EXCEPT those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose active infection with HCV antibody testing with reflex HCV RNA PCR (Rating I, A); one-time opt-out anti-HCV testing is recommended for all adults ≥18 years and with each pregnancy (I, B), with annual testing for people who inject drugs, men with HIV who have unprotected sex with men, and MSM on PrEP (IIa, C). Treatment is recommended for all persons with acute or chronic HCV infection EXCEPT those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy. Stage fibrosis noninvasively (FIB-4; biopsy not required). The simplified treatment algorithm applies only to treatment-naive adults and EXCLUDES prior HCV treatment, HBsAg positivity, current pregnancy, known or suspected HCC, prior liver transplantation, and any current or prior episode of decompensated cirrhosis; excluded patients are managed by the genotype/population-specific sections, not the simplified pathway. Treatment-naive WITHOUT cirrhosis (FIB-4 ≤3.25 and no other evidence of cirrhosis): glecaprevir 300 mg/pibrentasvir 120 mg once daily with food × 8 weeks, OR sofosbuvir 400 mg/velpatasvir 100 mg once daily × 12 weeks, both pangenotypic and equally recommended; pretreatment CBC, hepatic function panel, eGFR, quantitative HCV RNA, HIV, HBsAg, pregnancy test within 6 months, plus medication reconciliation for drug-drug interactions. Treatment-naive WITH compensated cirrhosis (Child-Pugh A): glecaprevir/pibrentasvir × 8 weeks for genotypes 1-6, OR sofosbuvir/velpatasvir × 12 weeks for genotypes 1, 2, 4, 5, and 6 only, in genotype 3 with compensated cirrhosis, baseline NS5A resistance testing is required before sofosbuvir/velpatasvir and the presence of Y93H changes the regimen; pretreatment labs within 3 months plus CTP score and liver ultrasound within 6 months. On treatment, no routine laboratory monitoring is required except counseling diabetic patients about hypoglycemia and monitoring INR in patients on warfarin. Decompensated cirrhosis (CTP class B or C, or any prior decompensation): refer to a practitioner with expertise, ideally at a liver transplant center; ALL protease-inhibitor-containing regimens (glecaprevir, grazoprevir, voxilaprevir) are contraindicated. Ribavirin-eligible, treatment-naive: sofosbuvir/velpatasvir + weight-based ribavirin × 12 weeks (all genotypes), or ledipasvir/sofosbuvir + ribavirin × 12 weeks for genotypes 1, 4, 5, 6; ribavirin-ineligible: sofosbuvir/velpatasvir (or ledipasvir/sofosbuvir for GT 1, 4, 5, 6) × 24 weeks without ribavirin; prior sofosbuvir-based or NS5A inhibitor-based treatment failure: sofosbuvir/velpatasvir + weight-based ribavirin × 24 weeks. In CTP class C, start ribavirin at 600 mg/day and increase as tolerated toward weight-based dosing. Cure is defined by quantitative HCV RNA undetectable ≥12 weeks after completing therapy (SVR12), checked with a hepatic function panel; patients without cirrhosis who achieve SVR need no further liver-related follow-up, while patients with cirrhosis continue HCC ultrasound surveillance every 6 months and variceal screening per AASLD guidelines after SVR. Repeat annual HCV RNA testing in anyone with ongoing exposure risk.

American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA), "Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection" (Patients With Decompensated Cirrhosis section), 2023 · reviewed 2026-07-23 ↗
Solomon SS … Mehta SH · Journal of Hepatology · IF 40.1 · PubMed ↗Permalink
Hepatology rct · n=96 · Jul 7, 2026 · J Gastro Hep · IF 3.5

Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.

New evidencePBC
Clinical takeawayContinue standard UDCA dose (13-15 mg/kg/day) in PBC patients with complete biochemical response; reduction to 5 mg/kg/day is unsafe due to high relapse risk. Consider monitoring 10 mg/kg/day cautiously in select patients (future studies needed). Do not reduce below 10 mg/kg/day in remission.
What it foundIn PBC patients with complete biochemical response (Paris-II criteria), reducing UDCA to 5 mg/kg/day increased 12-month relapse to 19.4% vs 0% on standard dose (13-15 mg/kg/day), while 10 mg/kg/day showed no significant difference (2.9% relapse).
ContextChallenges prior uncertainty about UDCA dose reduction safety in remission; confirms standard dose remains gold standard but introduces 10 mg/kg/day as a potential future option if validated.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance

Decision at stakethe optimal UDCA dosing strategy in PBC after biochemical remission

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. … After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.

AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance · reviewed 2026-10-25 ↗
He C … Zhang F · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
← Back to issue №1 Every section of this issue is one click away, at the top of this page. Follow Hepatology by RSS